TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07024641: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Sponsor: GigaGen, Inc. · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 48 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$1,419,432

Rescue Site Savings

+$939,624

Unlock Full NCT07024641 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07024641 Rescue Dossier →